Systematic Review of Tocilizumab for Rheumatoid Arthritis: A New Biologic Agent Targeting the Interleukin-6 Receptor Review uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • Arthritis, Rheumatoid
  • Receptors, Interleukin-6

abstract

  • The short-term efficacy and safety profile of TCZ is promising. Additional long-term safety data are needed to better characterize the risk-benefit profile of this agent.

publication date

  • April 2012

Research

keywords

  • Review

Identity

Language

  • eng

PubMed Central ID

  • PMC3805022

Digital Object Identifier (DOI)

  • 10.1016/j.clinthera.2012.02.014

PubMed ID

  • 22444783

Additional Document Info

start page

  • 788

end page

  • 802.e3

volume

  • 34

number

  • 4